The Big Pharma axe: Merck cuts chikungunya vax, Bristol Myers drops CytomX-partnered program, and more
As fourth quarter earnings come in, Big Pharmas are disclosing changes to their pipelines during their investor calls, and sometimes more quietly in presentation appendices …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.